Earnings call transcript: New China Life Insurance Q4 2025 reveals earnings miss, stock dips

New China Life Insurance reported 2025 operating revenue of CNY 157.8 billion and net profit of CNY 36.3 billion, both record highs, but its Q4 EPS of 1.10 missed the 1.96 estimate by 43.9%, sending the stock down 2.82% to USD 45.46. Management reiterated 2026 growth plans centered on participating insurance, bancassurance, asset allocation, and AI-driven service and risk management. The company also highlighted a 5.94% dividend yield, 12 straight years of dividend payments, and a solvency ratio above 200%.

Analysis

The core signal is not the headline earnings miss; it is the widening gap between reported accounting earnings and underlying franchise momentum. For a life insurer, that usually means near-term P&L is being distorted by investment timing, reserve normalization, or mix-shift costs while the embedded value engine remains intact. The market’s initial de-rating looks too mechanical if management can sustain high persistence and bancassurance-driven premium growth, because those are the inputs that typically re-rate the stock back toward book/EV rather than current-period EPS.

The bigger second-order effect is that the transition to participating products should compress near-term margins but reduce duration mismatch and improve liability stickiness over time. That is a favorable setup in a low-rate world if asset returns stay above crediting costs; it also makes the insurer more resilient to regulatory and rate volatility than peers who are still relying on spread-heavy traditional savings products. The downside is that execution risk is concentrated: if the participating mix grows faster than underwriting/ALM capabilities, the market will punish the stock with a lower multiple even if premium volume holds up.

On the asset side, the message is that management is consciously taking more equity and long-duration risk, which should help in a reflationary or equity-led tape but will raise reported volatility in down markets. That means the stock can outperform in a stable-to-rising China beta regime and underperform sharply if growth or market sentiment deteriorates. The dividend remains an important support, but the real catalyst for a sustained rerating is proof that higher-risk assets and participating liability growth are translating into stable EV expansion, not just one-year premium momentum.

Contrarian takeaway: the move may be overdone on the downside because investors are anchoring on EPS rather than the quality of franchise transition. The miss is less important than whether the company can convert its distribution scale into durable, fee-like value creation through persistence and cross-sell. If that happens, the stock should trade more like a capital-returning franchise with operating leverage than a simple earnings-miss story.

Key Decisions for Investors

• Buy the post-earnings weakness in 1336.HK on a 1-3 week horizon if the stock stabilizes above the post-gap close; use a 5-7% trailing stop because the dividend and valuation floor should limit downside unless guidance deteriorates.
• Pair trade: long 1336.HK / short a peer life insurer with weaker bancassurance and less visible product transition over the next 1-2 months; the relative winner should be the name with better persistence and stronger ALM flexibility.
• If options liquidity is sufficient, buy 3-6 month call spreads on 1336.HK to express a re-rating toward book value/EV as the market digests the participating-product transition; risk/reward is attractive if management sustains premium growth without a margin reset.
• Avoid chasing the dip in pure value terms until there is confirmation that participating mix expansion is not impairing NBV margin; the cleanest entry is after the next monthly sales data or management commentary on persistency trends.
• Monitor China long-end rates and equity beta as the key macro catalyst set; a further fall in yields or a risk-off tape would warrant reducing exposure because the thesis depends on asset returns offsetting liability duration pressure.